만성 C형간염 환자에서 페그인터페론과 리바비린 병합요법의 치료효과: 통합 분석
분야
의약학 > 내과학
저자
박수용 ( Soo Yong Park ) , 임민영 ( Min Young Rim ) , 여인구 ( In Ku Yo ) , 하민수 ( Min Su Ha ) , 김주승 ( Ju Seung Kim ) , 이지원 ( Ji Won Lee ) , 정영걸 ( Young Kul Jung ) , 권오상 ( Oh Sang Kwon ) , 김연수 ( Yun Soo Kim ) , 최덕주 ( Duck Joo Choi ) , 김주현 ( Ju Hyun Kim )
발행기관
대한소화기학회
간행물정보
대한소화기학회지 2012년, 제60권 제5호, 306~314쪽(총9쪽)
파일형식
07811286.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    4,000원
    적립금
    120원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. Methods: Twenty-eight papers related to the therapeutic effect of combination therapy in CHC patients were analyzed based on pooled analysis. Results: Based on the analysis for genotype 1 in Korea, early virologic response (EVR), end of treatment response (ETR), and sustained virologic response (SVR) were 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543). The EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516). Data from other Asians showed that EVR and SVR for genotype 1 were 88.9% (290/326) and 64.4% (491/762) respectively and 88.8% (135/152), and 79.4% (151/190) for genotype 2 and 3 respectively. In Western, EVR and SVR for genotype 1 were 51.3% (1,981/3,860) and 42.4% (1,798/4,231) respectively, and for genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Based on the comparative analysis, no statistical difference in SVR between Koreans and other Asians (p=0.955) was observed; However, the SVR of Koreans was higher with significance than that of Westerns (p<0.001) On the other hand, there was no difference what so ever, in SVR for genotype 2 amongst the different races. Conclusions: The SVR of combination therapy for the Korean chronic hepatitis C patients was similar to other Asians but higher than Westerns. (Korean J Gastroenterol 2012;60:306-314)
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.